Kinneret Advisory LLC purchased a new position in shares of Metlife Inc (NYSE:MET) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,330 shares of the financial services provider’s stock, valued at approximately $178,000.
Several other institutional investors have also recently added to or reduced their stakes in the business. Vivaldi Capital Management LLC purchased a new position in shares of Metlife during the 4th quarter worth about $290,000. Brown Advisory Inc. lifted its holdings in shares of Metlife by 68.9% during the 4th quarter. Brown Advisory Inc. now owns 55,638 shares of the financial services provider’s stock worth $2,284,000 after acquiring an additional 22,698 shares during the period. Brown Advisory Securities LLC lifted its holdings in shares of Metlife by 77.2% during the 4th quarter. Brown Advisory Securities LLC now owns 74,002 shares of the financial services provider’s stock worth $3,085,000 after acquiring an additional 32,246 shares during the period. Stifel Financial Corp lifted its holdings in shares of Metlife by 7.7% during the 4th quarter. Stifel Financial Corp now owns 1,037,337 shares of the financial services provider’s stock worth $42,556,000 after acquiring an additional 73,812 shares during the period. Finally, Berman Capital Advisors LLC purchased a new position in shares of Metlife during the 4th quarter worth about $31,000. 74.09% of the stock is currently owned by institutional investors.
NYSE MET opened at $44.84 on Friday. Metlife Inc has a one year low of $37.76 and a one year high of $48.92. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.14 and a current ratio of 0.14. The company has a market capitalization of $42.92 billion, a P/E ratio of 8.32, a price-to-earnings-growth ratio of 0.96 and a beta of 1.20.
Metlife (NYSE:MET) last posted its quarterly earnings results on Wednesday, February 6th. The financial services provider reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.05. Metlife had a net margin of 7.53% and a return on equity of 10.24%. The firm had revenue of $15.40 billion for the quarter, compared to analyst estimates of $15.84 billion. During the same quarter last year, the firm posted $0.64 earnings per share. Metlife’s revenue for the quarter was up .0% compared to the same quarter last year. Equities research analysts predict that Metlife Inc will post 5.48 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 13th. Investors of record on Tuesday, February 5th were issued a $0.42 dividend. The ex-dividend date of this dividend was Monday, February 4th. This represents a $1.68 annualized dividend and a yield of 3.75%. Metlife’s payout ratio is 31.17%.
In other Metlife news, EVP Steven J. Goulart sold 10,292 shares of the stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $44.40, for a total value of $456,964.80. Following the completion of the sale, the executive vice president now owns 93,214 shares of the company’s stock, valued at $4,138,701.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carlos M. Gutierrez acquired 6,400 shares of the stock in a transaction on Monday, December 17th. The stock was purchased at an average cost of $39.04 per share, with a total value of $249,856.00. Following the transaction, the director now directly owns 4,668 shares of the company’s stock, valued at $182,238.72. The disclosure for this purchase can be found here. Company insiders own 0.34% of the company’s stock.
Several brokerages have recently weighed in on MET. Zacks Investment Research lowered shares of Metlife from a “buy” rating to a “hold” rating in a report on Monday, January 21st. ValuEngine upgraded shares of Metlife from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. Bank of America upgraded shares of Metlife from a “neutral” rating to a “buy” rating and set a $44.06 price objective on the stock in a report on Wednesday, January 16th. Argus reiterated a “buy” rating on shares of Metlife in a report on Tuesday, February 12th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Metlife in a report on Tuesday, January 8th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Metlife has a consensus rating of “Buy” and an average price target of $52.92.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Read More: Buy-Side Analysts
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.